Tenecteplase: A Growing Role in Acute Ischemic Stroke Treatment

As the only FDA-approved medical treatment for acute ischemic stroke (AIS), alteplase (tPA) has long been the standard of care. Although, a newer fibrinolytic agent, tenecteplase, is gaining traction due to recent clinical trial findings, streamlined workflows and potential cost-effectiveness. This article explores the current evidence surrounding tenecteplase, its practical considerations, and its increasing utilization in routine stroke care.

Understanding Acute Ischemic Stroke and Thrombolysis

Acute ischemic stroke occurs when a blood clot blocks an artery supplying the brain, depriving brain tissue of oxygen and nutrients. Rapid restoration of blood flow is critical to minimize brain damage. Thrombolysis, the use of medications to dissolve blood clots, is a key treatment strategy. Both alteplase and tenecteplase are thrombolytic agents designed to achieve this.

Alteplase: The Established Standard

Alteplase, a recombinant form of tissue plasminogen activator (tPA), works by converting plasminogen to plasmin, an enzyme that breaks down fibrin, the main component of blood clots [1]. While effective, alteplase has pharmacokinetic limitations, including a short half-life of less than 6 minutes and the need for a continuous infusion to maintain therapeutic drug levels [1]. Even short delays in initiating the continuous infusion can lead to a significant drop in drug concentration.

Tenecteplase: A Promising Alternative

Tenecteplase also promotes fibrinolysis by converting plasminogen to plasmin, but it exhibits more favorable pharmacokinetic and pharmacodynamic properties compared to alteplase [2]. It is easier to administer, typically as a single bolus injection, simplifying clinical workflows. Animal studies have demonstrated these advantages [2].

Clinical Evidence Supporting Tenecteplase

Recent clinical trials have investigated the efficacy of tenecteplase in various stroke scenarios. Studies suggest potential advantages over alteplase, particularly in specific patient populations and time windows. Research is ongoing to determine whether tenecteplase is superior or non-inferior to alteplase as standard-of-care [3].

One trial is specifically evaluating the benefits of tenecteplase initiated between 4.5 and 24 hours after symptom onset in patients with acute ischemic stroke due to non-large vessel occlusion with salvageable brain tissue [4].

Real-World Implementation and Considerations

The increasing adoption of tenecteplase in routine stroke care raises several practical considerations:

• Off-label Use: The use of tenecteplase may be considered off-label in certain situations, requiring careful evaluation and patient consent.
• Patient Consent: Patients should be fully informed about the risks and benefits of both alteplase and tenecteplase before making a treatment decision.
• Stroke Center Accreditation: Transitioning to tenecteplase may require adjustments to stroke center protocols and accreditation standards.
• Cost Savings: Tenecteplase may offer cost savings compared to alteplase due to its simpler administration and potentially reduced hospital stay.

The Future of Thrombolysis

Tenecteplase represents a significant advancement in acute ischemic stroke treatment. As more evidence emerges and clinical workflows are refined, it is poised to play an increasingly essential role in improving outcomes for stroke patients. Ongoing research will continue to define its optimal use and further refine stroke care protocols.